title: [Therapeutic importance and tolerance of coated 50 mg Vectarion tablets (almitrine bismesylate) at a dosage of 100 mg/day. Study of blood gas, clinical and biological results after a year of long-term treatment].
abstract: The objectives of this study, in which Almitrine bismesylate was administered for one year in chronic bronchitics with obstructive hypoxia, were to assess its clinical and gasometric efficacy and its clinical, laboratory, spirometric and electrocardiac acceptability. The blood gas results show a significant rise in PaO2 (p less than 0.001) rising by 5.5 mmHg after 6 months (T6) and by 6.0 mmHg after 12 months (T12) in comparison with the value at the study's onset. The PaCO2 fell by 3.3 mmHg at T6 and 2.7 mmHg at T12 (p less than 0.001). The dyspnoea of the patient, scored by the doctor on a scale of severity from 0 to 5 was situated on a mean of 3.3 points at the beginning of the study. It was significantly reduced by 0.8 points at T6 and by 0.9 points at T12 (p less than 0.001). The percentage of patients hospitalised during the course of the study fell significantly in comparison with the previous year, from 68% to 49% (p less than 0.001). The improvement in clinical status and in blood gases bore no relation to changes in respiratory function. The clinical acceptability of the product was good; few side effects were observed and the respiratory, digestive and neurological problems were often pre-existing. They only led to cessation of treatment in three cases. The electrocardiogram was unchanged. The laboratory investigations was unchanged, with the exception of a fall in red blood cells in relation to the correction of the hypoxaemia in polycythaemic patients.
authors.forename: J C
authors.initials: JC
authors.lastname: Ansquer
authors.forename: A
authors.initials: A
authors.lastname: Bertrand
authors.forename: B
authors.initials: B
authors.lastname: Blaive
authors.forename: J
authors.initials: J
authors.lastname: Charpin
authors.forename: J
authors.initials: J
authors.lastname: Chrétien
authors.forename: G
authors.initials: G
authors.lastname: Decroix
authors.forename: J C
authors.initials: JC
authors.lastname: Kalb
authors.forename: J
authors.initials: J
authors.lastname: Lissac
authors.forename: F B
authors.initials: FB
authors.lastname: Michel
authors.forename: P
authors.initials: P
authors.lastname: Morère
mesh_terms: D015765:Almitrine; D001991:Bronchitis / Q000188:drug therapy* / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002908:Chronic Disease; D004361:Drug Tolerance; D004417:Dyspnea / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011659:Pulmonary Gas Exchange; D012129:Respiratory Function Tests
chemical_list: D000697:Central Nervous System Stimulants; D010879:Piperazines; D015765:Almitrine
vernacular_title: Intérêt thérapeutique et acceptabilité du Vectarion 50 mg comprimés enrobés (bismésilate d'almitrine) à la dose de 100 mg/jour. Etude des résultats gazométriques, cliniques et biologiques en traitement prolongé pendant 1 an.